MESOBLAST REPORTS RYONCIL ® NET REVENUES OF US$36M FOR THE QUARTER AND US$115M FOR FIRST FULL YEAR OF PRODUCT LAUNCH Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300...